glp-1-directed nmda receptor antagonism for obesity treatment GLP−1 agonists the of obesity: Role as a promising approach PDF) GLP-1-directed NMDA receptor antagonism
Description
Nightmares are not listed among recognised side effects in official UK prescribing information, and large-scale clinical trials have not identified sleep disturbances as a significant adverse event
Frito-Lay remains very quiet on the long-term effect of GLP-1 drugs on its business
Originally developed for diabetes, they have been shown to significantly aid in weight loss
Additionally, only for initial analysis (Venn diagrams), we included SGLT2i (empagliflozin, dapagliflozin) and metformin
